Vaccines for Virus from Parvoviridae Family

Creative Biolabs is a world leader in the field of viral vaccine development. With our strong expertise and advanced platform in the vaccine field, we are therefore confident in offering the best vaccine development services for different types of diseases caused by virus from Parvoviridae family, including parvovirus B19, canine parvovirus, feline panleukopenia virus, and porcine parvovirus.

Background of Virus from Parvoviridae Family

The Parvoviridae are an ancient family of viruses that package a ssDNA genome and the parvoviruses are the smallest among the animal DNA viruses. Parvoviridae, which are divided into two subfamilies, the Densovirinae and the Parvovirinae, can infect both vertebrate and insects and are related to a wide range of diseases in insects, animals, and humans. The genome is a linear, single-stranded polydeoxynucleotide chain with typically about 5 kilobases in size and usually contains two large open reading frames (ORF1 and ORF2).

Vaccines for Parvovirus B19

Parvovirus B19, the only known human pathogenic parvovirus, is a small icosahedral virus that belongs to the Parvoviridae family and is associated with a wide range of disease manifestations. The capsid of parvovirus B19 is formed from 60 subunits of only two proteins, VP1 (5% abundance) and VP2 (95% abundance), which are identical in their sequence except for an extra sequence of 227 amino acids at the VP1 N-terminus. Like many other non-enveloped viral structural proteins, parvovirus B19 VP2 spontaneously forms virus-like particles (VLPs), but the parvovirus B19 VP1 alone cannot form VLPs. Using genetic engineering techniques, capsid proteins have been expressed in mammalian and insect cell lines where they self-assemble in the absence of B19 DNA to form recombinant empty capsids. These VLPs are effective in protecting the host from parvovirus infection and are candidates for the prevention and control of parvovirus B19 infection.

Vaccines for Canine Parvovirus

Canine parvovirus (CPV), which belongs to the genus Parvovirus, is a non-enveloped, single-stranded DNA virus that can cause severe myocarditis, enteritis, and lymphopenia in dogs. Several CPV variants have emerged since it has spread worldwide, including CPV-2, CPV-2a, CPV-2b, and CPV-2c. Conventional vaccines against CPV include killed and modified live virus (MLV) vaccines. The killed vaccine requires high doses of antigen per immunization and adjuvant, while MLV could be excreted after vaccination and not recommended during pregnancy. In addition, newborns are generally considered unsuitable for vaccination due to passive transfer of maternal antibodies leading to antigen clearances and immaturity of their immune system. To solve these problems, Creative Biolabs has developed new CPV vaccines, including recombinant vaccines and VLPs that are effective in preventing and controlling CPV.

Vaccines for Feline Panleukopenia Virus

Feline parvovirus (FPV), feline herpesvirus (FHV), and feline calicivirus (FCV) all cause major infectious diseases in cats. Because FPV, FCV, and FHV infections are very prevalent, easily transmitted and/or cause serious illness, vaccination of all cats was recommended by the Advisory Board on Cat Diseases. FPV, the causative agent of a contagious, serious disease in cats, belongs to the genus Parvovirus of the virus family Parvoviridae. FPV is known also to infect other members of the Felidae, as well as raccoons, mink and foxes. FPV-induced panleukopenia is often fatal, especially in young kittens; it is highly contagious and particularly resistant in the environment. In addition to strengthening management measures, one of the important prevention methods is vaccination. Currently, vaccines against FPV are generally based on avirulent, replication competent virus strains (modified live vaccines, MLV) or combined vaccines.

Vaccines for Porcine Parvovirus

Porcine parvovirus (PPV) is the main pathogen causing reproductive failure in swine. PPV is a ubiquitous virus present around the world that causes increasing economic losses due to the industrialization of pig farming. PPV is a small, non-enveloped icosahedral virus and has a single-stranded DNA genome surrounded by non-enveloped icosahedral particles, which are composed of three structural proteins: VP1, VP2, and VP3, of which VP2 is the major component. The capsid VP2 protein can assemble into VLPs alone, which contains most of the B cell epitopes that play a key role in triggering neutralizing antibodies. At present, classic vaccines based on inactivated viruses can effectively prevent PPV-induced infections, but the possibility of incomplete virus inactivation can lead to the development of the disease. Therefore, a new generation of vaccines should be developed. The VP2-based VLPs consists of viral structural proteins, has a structure similar to natural virus particles, and is capable of inducing humoral and cellular immune responses, and is therefore considered to be a very promising candidate vaccine for PPV.

Creative Biolabs is a professional vaccine development company with years of experience in viral vaccine development services. We have experienced experts and advanced platforms to provide quality vaccine service for the virus from Parvoviridae family. If you have any needs in this regard, please let us know as soon as possible.

All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.